All News
Dr Palomäki on influence of MUC5B promotor variant on ILD risk in RA and non-RA. Lifetime risk ILD 14.5% for RA+MUC5B+, 5.2% for RA+MUC5B-, 3.9% RA-MUC5B+ 1.3% RA-MUC5B- @RheumNow #EULAR2021 Abstr#OP0007 https://t.co/BnexQE1Pw9
Richard Conway RichardPAConway ( View Tweet)
Dr Ponte presenting on use of halo sign on TA US to monitor GCA disease activity. Seems good, present and increased in 16/17 (94.1%) cases of first disease relapse @RheumNow #EULAR2021 #AbstrOP0055 https://t.co/T6hKjkb4AT
Richard Conway RichardPAConway ( View Tweet)
Abs#OP0009 presents 8 min web-based video for COVID vax education sent via text message. 76% more likely to get vax. #EULAR2021. @RheumNow. Pts need to hear from their rheumatologists our thoughts on vax, ideally in person, but phone is great outreach https://t.co/aimGBufYpe
Eric Dein ejdein1 ( View Tweet)
Excellent job by @jeffsparks @zach_wallace_md @rheum_covid on Abs#0P0006 at #EULAR2021.
⭐️RTX and JAKi: increased COVID severity, not seen in IL-6 or ABA. Critical findings, but confounding role of co-morbidities/ILD/cancer, esp in RTX patients? @RheumNow
Eric Dein ejdein1 ( View Tweet)
Dr. Tani: Who has trouble tapering below 5mg/d prednisone in SLE
☑️Older patients
☑️High disease activity
☑️Skin and MSK manifestations
☑️Pts treated before 2000.
Try to avoid long-term steroid usage early in the disease course, as it gets harder over time. #EULAR2021, @RheumNow
Eric Dein ejdein1 ( View Tweet)
Excellent talk by @LCalabreseDO on the balance of the immune response!
⭐️Exhausted T cells seen in rheumatic dz, chronic infections, cancers, severe COVID-19
⭐️CPI for treatment of latent infections? CPI for treatment of COVID? 🤔
Abs#OP7137 #EULAR2021 @RheumNow https://t.co/18rvFkpPTx
Robert B Chao, MD doctorRBC ( View Tweet)
Secukinumab effective in AS patients, irrespective of gender
AQUILA 52 week study
⭐️improvement in BASDAI, PGA, severity of depressive mood in both men and women
⭐️women had overall higher disease burden in global functioning and depressive mood
POS0899
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
Dr Atienza-Mateo presents abstract #POS0595 on abatacept in RA-ILD. Abatacept surprisingly appeared to be equally good in stabilising FVC and DLCO in both UIP and NSIP patterns in RA-ILD. @RheumNow #EULAR2021 Abstr#POS0595 https://t.co/kHUxWXnaBG
Richard Conway RichardPAConway ( View Tweet)
I'm presenting data on COVID-19 in Irish rheumatic disease patients. Age, number comorbidities, glucocorticoids, associated increased hospitalisation. Inflammatory arthritis associated decreased hospitalisation. @RheumNow #EULAR2021 #AbstrPOS1162 https://t.co/0gKxiMNYTf
Richard Conway RichardPAConway ( View Tweet)
#EULAR2021 recommendations: RMDs face no more risk of contracting COVID-19, no current evidence of worse prognosis. Do you tell patients similar stats? @RheumNow
Eric Dein ejdein1 ( View Tweet)
#EULAR2021 recommendations on mgmt of RMD in COVID: continue treatment if symptom free, steroids at lowest dose. @Rheumnow. https://t.co/U5zr7EHvTv
Eric Dein ejdein1 ( View Tweet)
Seeing the sites of Paris at virtual #eular2021. Follow on @RheumNow along with @RichardPAConway @MeralElRamahiMD @Yuz6Yusof @Stiddyo @KDAO2011 @uptoTate @AurelieRheumo @drdavidliew @Janetbirdope https://t.co/w18REG08nz
Eric Dein ejdein1 ( View Tweet)
@RheumNow I will be tweeting alongside an amazing team @RichardPAConway @MeralElRamahiMD @Stiddyo @KDAO2011 @uptoTate @Yuz6Yusof
@drdavidliew @ejdein1 @Janetbirdope @TammyTilley & last but not least Dr Cush! Follow them and @Rheumnow to stay tuned for the latest science! #EULAR2021
Aurelie Najm AurelieRheumo ( View Tweet)
There seem to be quite a few #EULAR2021 abstracts that are identical (or nearly) to #ACR20 abstracts, eg mavrilimumab and GUSTO in vasculitis oral presentation section. Have the rules changed?
Richard Conway RichardPAConway ( View Tweet)
Guselkumab (IL-23i) 52 week extension study in PsA pts from DISCOVER 1 and 2 ⭐️sustained DAPSA LDA/remission ⭐️sustained PASDAS LDA/vLDA ⭐️sustained MDA POS1024 #EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
C-VIEW Study: Certolizumab reduced Anterior Uveitis flares in AxSpA
⭐️82% ⬇️ in uveitis flare event
⭐️reduction in axSpA disease activity
⭐️no new safety signals
POS0897 #EULAR2021 @RheumNow https://t.co/182iHfkSTY
Robert B Chao, MD doctorRBC ( View Tweet)
Longitudinal UK SLE inception cohort 273 pts found:
👉⬆️damage in 1st 3 yrs b/f stabilizing at lower rate
👉mortality uncommon in 1st 12 yrs, but can occur w/in 5 yrs of Dx.
👉unexpected⬆️mortality in Caucasians
38% deaths IHD, 23% infx
Abst#0111 #EULAR2021 @rheumnow @Lupusdoc https://t.co/wUwWaB4V2R
k dao KDAO2011 ( View Tweet)
Can you predict flares in SLE pts who achieved LLDAS? Retrospec cohort study from Portugal over 3 years of 292 pts who were in LLDAS, 31% flared. Flares seen more in: 👉pts who require ongoing Rx w/ immmunosuppr, GCs 👉pt w/+RNP Abst#0105 #EULAR2021 @RheumNow https://t.co/xfBqGh4pPP
k dao KDAO2011 ( View Tweet)
C3 and C4⬆️in SLE pregnancy like they would in pregnancies w/o SLE!
French GR2 prospective study of 290 SLE pregnancies quantifies mean C3 value⬆️by 28%, C4⬆️by 11% from 1st ➡️3rd trimester. Remember this when assessing disease activity. #EULAR2021 Abstr #0103 @rheumnow https://t.co/TXjO4mjNJE
k dao KDAO2011 ( View Tweet)
Definition of LLDAS: "A state assc w/low likelihood of adverse outcome, considering disease activity and medication safety; it must be favorable, deployable, feasible, and attainable," - Dr. E Morand #EULAR2021 @RheumNow https://t.co/oMMU3AjhmX
k dao KDAO2011 ( View Tweet)